Methylene Blue: What the Evidence Says — and the Real Risks

Methylene blue is a regulated drug with a documented capacity for serious harm, not a casual wellness supplement — and the marketing has run well ahead of the human evidence.

The short answer

Methylene blue is a synthetic dye and a regulated medicine. Its one clearly established medical role is as a hospital treatment for acquired methemoglobinemia, a blood disorder, where it is given intravenously by clinicians [Clifton 2025]. It is now being repackaged and sold online as a nootropic, longevity and "mitochondrial" supplement, with claims about sharper memory, more energy and slower ageing.

Here is the honest position the evidence supports: most of those benefit claims rest on laboratory and animal work, or on small, short human studies. The drug also carries genuine, documented risks — including potentially fatal serotonin syndrome when combined with common antidepressants, dangerous reactions in people with G6PD deficiency, and quality problems with what is actually in the bottle. It is not a casual supplement, and the marketing has run well ahead of the human data.

What methylene blue actually is

Methylene blue (methylthioninium chloride) is a phenothiazine dye first synthesised in the 1870s. It stains tissues, dyes fabrics, treats fish parasites in aquariums, and has a long history in laboratories and medicine.

Its legitimate, evidence-backed medical uses are narrow and supervised:

• Acquired methemoglobinemia. This is its primary licensed indication. In this condition, the iron in haemoglobin is oxidised so it can no longer carry oxygen properly. Given intravenously, methylene blue is reduced in the body to leucomethylene blue, which converts the iron back to its oxygen-carrying form [Clifton 2025]. The standard hospital dose is around 1 mg/kg given slowly into a vein, repeated once if needed [Clifton 2025].
• Other supervised clinical uses. It is used in some surgical settings as a visualising dye, and has been studied in conditions such as vasoplegic syndrome and ifosfamide-induced encephalopathy. These are clinician-led, in-hospital uses, not self-care.

Note the gap. The licensed use is an injectable, emergency treatment. The product being sold to consumers is an oral, low-dose "wellness" drop. The two are not the same thing, and a licence for one does not validate the other.

Why it is marketed as a nootropic and "longevity" supplement

The supplement story is built almost entirely on a mechanism: mitochondria, the structures that generate energy inside cells.

At low concentrations, methylene blue can act as an alternative electron carrier. In simplified terms, it can accept electrons and pass them along the mitochondrial respiratory chain, potentially bypassing certain bottlenecks and increasing the activity of the enzyme cytochrome c oxidase [Rojas 2012; Tucker 2018]. In cell and animal models it has been reported to raise oxygen consumption, increase the activity of energy-producing enzymes and act as an antioxidant at low doses [Tucker 2018; Xue 2021].

Importantly, methylene blue shows what researchers call a hormetic, biphasic dose-response: helpful-looking effects at very low concentrations can reverse into harmful, pro-oxidant effects at higher ones [Rojas 2012]. This is the opposite of "if a little is good, more is better" — and it is exactly the assumption casual self-dosing tends to make.

From this mechanistic foundation, marketers extrapolate to claims about focus, memory, mood, energy, "anti-ageing" and brain protection. The leap from a plausible mechanism in a dish to a measured benefit in a healthy person is the central problem here, and it is the same pattern we see across the wider supplement market. A mechanism is a hypothesis, not a result.

What the human evidence actually shows

Strip away the cell and animal work, and the human data are thin.

The single most cited human study is a 2016 functional MRI experiment in 26 healthy adults. A single low oral dose of methylene blue was associated with increased brain activity on attention and short-term memory tasks, and a roughly 7% increase in correct responses during a memory-retrieval task, compared with placebo [Rodriguez 2016]. That is a real, peer-reviewed finding — but it is one small, acute, single-dose study in healthy volunteers, measuring task performance and brain imaging, not long-term cognition, real-world function or safety. The authors themselves framed it as a foundation for future trials [Rodriguez 2016].

The most informative longevity-adjacent evidence comes from Alzheimer's research, because a methylene blue derivative was taken all the way to large clinical trials. A stabilised reduced form, leuco-methylthioninium (LMTM, also called TRx0237), was tested as a tau-aggregation inhibitor in a randomised, double-blind phase 3 trial of 891 people with mild-to-moderate Alzheimer's disease. As a monotherapy and add-on across the primary analysis, it did not slow cognitive or functional decline versus the comparator [Gauthier 2016]. A widely criticised subgroup analysis suggested benefit in a small group not taking other Alzheimer's drugs, but that finding was not from the trial's main comparison and does not carry the same weight — a useful illustration of how "evidence-based" language gets stretched.

So the picture is: encouraging preclinical mechanisms, one small positive acute human imaging study, and a large rigorous trial of a close derivative that failed its main endpoints. That is a long way from established benefit for healthy people seeking an edge.

Claims versus evidence

The honest summary: outside its licensed medical role, the benefits are largely preclinical or extrapolated, and the one supportive human study is small and short. Before reading any of these claims as settled, it is worth knowing how to read a clinical trial — particularly the difference between a mechanism, a surrogate marker and a real outcome.

The risks — read this part carefully

This is where methylene blue stops behaving like a supplement and behaves like the drug it is. The risk section matters more than the benefit section.

Serotonin syndrome — the most serious concern

Methylene blue is a potent inhibitor of monoamine oxidase A (MAO-A), the enzyme that breaks down serotonin [Ramsay 2007]. Combine an MAO inhibitor with drugs that raise serotonin and you can trigger serotonin syndrome — a potentially life-threatening reaction involving agitation, rapid heart rate, high temperature, muscle rigidity and confusion.

Published case reports of methylene blue–associated serotonin toxicity, several of them serious and at least one fatal, are well documented, mostly when it was given to patients already taking serotonergic medication [Lee 2023]. The drugs of concern include:

• SSRIs and SNRIs (common antidepressants)
• MAO inhibitors
• Bupropion, buspirone, mirtazapine, clomipramine
• Linezolid (an antibiotic), some opioids (e.g. tramadol, pethidine) and dextromethorphan

The risk is serious enough that the licensed product carries a boxed warning, the strongest category, advising against use with serotonergic drugs [Provayblue 2024]. If you take any antidepressant, this single interaction is reason enough not to experiment.

G6PD deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzyme disorder affecting hundreds of millions of people worldwide, often without their knowledge. In people who are G6PD-deficient, methylene blue can trigger the breakdown of red blood cells (haemolytic anaemia) and can paradoxically worsen the very methemoglobinemia it is meant to treat [Youngster 2024; Clifton 2025]. It is considered contraindicated in this group [Clifton 2025]. Most people who buy a supplement online have never been tested.

Dose-dependent toxicity and other effects

Methylene blue is reasonably tolerated at low therapeutic doses but becomes toxic as the dose rises [Clifton 2025]:

• Higher single or cumulative doses (in the region of 7 mg/kg and above) are linked to nausea, vomiting, chest pain, breathlessness, low blood pressure and abnormal heart rhythms [Clifton 2025].
• Very high doses (around 15 mg/kg and above) can themselves cause haemolysis [Clifton 2025].
• It causes blue-green discolouration of urine, stool, saliva and sometimes skin — harmless but disconcerting, and it can interfere with pulse oximeter readings.
• It is generally not recommended in pregnancy, where it has been linked to fetal harm [Clifton 2025].

Grade and purity confusion

Methylene blue is sold in very different grades. Aquarium and industrial grades are not manufactured to the purity standards required for human use and can contain heavy metals and other contaminants; pharmaceutical (USP) grade is held to far stricter purity limits. Because consumer "supplements" sit largely outside medicines regulation, what is on the label is not guaranteed to be what is in the bottle, and a Certificate of Analysis from an independent lab is the exception rather than the rule. This is a structural weakness of the supplement category, not a quirk of one product — see how supplements are regulated. With a compound where the safe window is narrow and dose matters enormously, uncertainty about concentration and purity is not a minor detail.

Dosing confusion is part of the danger

A recurring theme above is dose. The licensed treatment is weight-based, intravenous and clinician-administered. The hormetic curve means low and high doses can do opposite things [Rojas 2012]. The toxicity thresholds are not far above the doses people discuss online. And the actual concentration in an unregulated product may be uncertain.

Put together, this means self-dosing is being attempted with a drug where small errors in amount, an unknown G6PD status, or a forgotten antidepressant can turn an experiment into a medical emergency. None of that is hypothetical — each element is documented in the references above.

The bottom line

Methylene blue is a real drug with a real, narrow, supervised medical role. The science behind its proposed cognitive and longevity benefits is genuinely interesting at the mechanistic level, but in humans it remains early: one small acute imaging study on the positive side, a large rigorous trial of a close derivative that failed on the other, and a great deal of cell and animal work in between [Rodriguez 2016; Gauthier 2016; Rojas 2012; Xue 2021].

The risk profile, by contrast, is not speculative. Serotonin syndrome with antidepressants, haemolysis in G6PD deficiency, dose-dependent toxicity and uncertain product quality are all well established [Ramsay 2007; Lee 2023; Youngster 2024; Clifton 2025]. When the hype clearly outruns the evidence and the downside includes documented serious harm, the cautious reading is the correct one. This is a drug, it is being sold as a supplement, and that mismatch is exactly where people get hurt.

Related Proco pages

• How supplements are regulated
• How "evidence-based" gets misused
• How to read a clinical trial
• What recovery actually means

Sources

Do not self-administer methylene blue; speak to a clinician first, and be especially cautious if you take any antidepressant or other serotonergic medication.